Supporting information Targeting Quorum Sensing: High-Throughput Screening to Identify Novel LsrK Inhibitors Viviana Gatta 1, Polina Ilina1, Alison Porter 2, #, Stuart McElroy 2,# and Päivi Tammela 1,* 1 Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014 Helsinki, Finland;
[email protected] (V.G.),
[email protected] (P.I.),
[email protected] (P.T.) 2 European Screening Centre, Biocity Scotland, Newhouse, ML1 5UH, UK;
[email protected] (A.P.),
[email protected] (S.M.) * Correspondence:
[email protected]; Tel.: +358-50-448 0886 # Current address: BioAscent Discovery Ltd., Newhouse ML1 5UH, UK;
[email protected] (A.P.);
[email protected] (S.M.) Table of contents: Assay development………………………………………………………………………………………...page 2 Results from primary screening…………………………………………………………………………..page 2-85 Dose-response experiments……………………………………………………………………….............page 86-89 Thermal shift assay and MST assay………………………………………………………………………page 90-91 AI-2 quorum sensing interference activity………………………………………………………………page 92 1 Figure S1: Optimization of LsrK and DPD concentrations: (a) S/B and (b) Z’ calculated for each tested combination of LsrK and DPD. Table S1. LsrK inhibition results from primary screening of the MicroSource Spectrum Library. Bioactivity and source refer to information provided as MicroSource annotations. Compounds were tested in singles at 50 µM, and sorted in the table according to their inhibitory effect.